• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Decrease in provider stigma is associated with improved quality health indicators among individuals receiving methadone in primary care centers in Ukraine.在乌克兰初级保健中心接受美沙酮治疗的个体中,提供者污名的减少与改善的健康质量指标相关。
Int J Drug Policy. 2025 Feb;136:104682. doi: 10.1016/j.drugpo.2024.104682. Epub 2024 Dec 19.
2
Supervised dosing with a long-acting opioid medication in the management of opioid dependence.在阿片类药物依赖管理中使用长效阿片类药物进行监督给药。
Cochrane Database Syst Rev. 2017 Apr 27;4(4):CD011983. doi: 10.1002/14651858.CD011983.pub2.
3
Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs.针具交换计划和阿片类药物替代疗法预防注射吸毒者丙型肝炎传播
Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012021. doi: 10.1002/14651858.CD012021.pub2.
4
Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease.用于慢性阻塞性肺疾病自我管理的计算机和移动技术干预措施。
Cochrane Database Syst Rev. 2017 May 23;5(5):CD011425. doi: 10.1002/14651858.CD011425.pub2.
5
Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine.设计并实施了一项 2 型混合前瞻性随机试验,旨在将阿片类激动剂治疗整合到乌克兰初级保健诊所中。
Contemp Clin Trials. 2024 Nov;146:107690. doi: 10.1016/j.cct.2024.107690. Epub 2024 Sep 14.
6
Buprenorphine for managing opioid withdrawal.丁丙诺啡用于管理阿片类药物戒断。
Cochrane Database Syst Rev. 2017 Feb 21;2(2):CD002025. doi: 10.1002/14651858.CD002025.pub5.
7
Risk-stratified Care Improves Pain-related Knowledge and Reduces Psychological Distress for Low Back Pain: A Secondary Analysis of a Randomized Trial.风险分层护理可提高腰痛患者的疼痛相关知识并减轻心理困扰:一项随机试验的二次分析
Clin Orthop Relat Res. 2025 Apr 1;483(4):607-620. doi: 10.1097/CORR.0000000000003351. Epub 2025 Jan 21.
8
Strategies to improve smoking cessation rates in primary care.提高初级保健中戒烟率的策略。
Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD011556. doi: 10.1002/14651858.CD011556.pub2.
9
Integrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge.将美沙酮纳入乌克兰初级保健机构:对提供者耻辱感和知识的影响。
J Int AIDS Soc. 2024 Feb;27(2):e26202. doi: 10.1002/jia2.26202.
10
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.

本文引用的文献

1
Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine.设计并实施了一项 2 型混合前瞻性随机试验,旨在将阿片类激动剂治疗整合到乌克兰初级保健诊所中。
Contemp Clin Trials. 2024 Nov;146:107690. doi: 10.1016/j.cct.2024.107690. Epub 2024 Sep 14.
2
High rates of deferring antiretroviral treatment for patients with HIV and substance use disorders: Results from a national sample of HIV physicians in Ukraine.高比例的 HIV 合并物质使用障碍患者延迟抗逆转录病毒治疗:来自乌克兰全国 HIV 医生样本的结果。
PLoS One. 2024 Jul 19;19(7):e0305086. doi: 10.1371/journal.pone.0305086. eCollection 2024.
3
Integrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge.将美沙酮纳入乌克兰初级保健机构:对提供者耻辱感和知识的影响。
J Int AIDS Soc. 2024 Feb;27(2):e26202. doi: 10.1002/jia2.26202.
4
Integrated biobehavioral surveillance among people who inject drugs in Ukraine, 2007-2020.2007 - 2020年乌克兰注射吸毒人群的综合生物行为监测
Int J Drug Policy. 2024 Jan 11:104319. doi: 10.1016/j.drugpo.2024.104319.
5
Preliminary analysis of self-reported quality health indicators of patients on opioid agonist therapy at specialty and primary care clinics in Ukraine: A randomized control trial.乌克兰专科和初级保健诊所接受阿片类激动剂治疗患者自我报告的健康质量指标的初步分析:一项随机对照试验。
PLOS Glob Public Health. 2022 Nov 2;2(11):e0000344. doi: 10.1371/journal.pgph.0000344. eCollection 2022.
6
Exploring Malaysian Physicians' Intention to Discriminate Against Gay, Bisexual, and Other Men Who Have Sex with Men Patients.探讨马来西亚医生歧视男同性恋、双性恋和其他与男性发生性关系的男性患者的意图。
LGBT Health. 2023 Feb-Mar;10(2):169-175. doi: 10.1089/lgbt.2021.0452. Epub 2022 Oct 14.
7
Intervention Stigma toward Medications for Opioid Use Disorder: A Systematic Review.干预污名化与阿片类药物使用障碍治疗:系统综述
Subst Use Misuse. 2021;56(14):2181-2201. doi: 10.1080/10826084.2021.1975749. Epub 2021 Sep 20.
8
A systematic review of stigma interventions for providers who treat patients with substance use disorders.对治疗物质使用障碍患者的医护人员的污名干预措施的系统评价。
J Subst Abuse Treat. 2021 Dec;131:108486. doi: 10.1016/j.jsat.2021.108486. Epub 2021 May 25.
9
A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder.对患者和医疗服务提供者关于阿片类物质使用障碍治疗药物观点的系统评价。
J Subst Abuse Treat. 2020 Dec;119:108146. doi: 10.1016/j.jsat.2020.108146. Epub 2020 Sep 22.
10
Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study.印度尼西亚、乌克兰和越南艾滋病毒阳性吸毒者对影响阿片类激动剂治疗使用率的因素的患者和提供者观点:HPTN 074 研究。
Harm Reduct J. 2020 Oct 1;17(1):69. doi: 10.1186/s12954-020-00415-x.

在乌克兰初级保健中心接受美沙酮治疗的个体中,提供者污名的减少与改善的健康质量指标相关。

Decrease in provider stigma is associated with improved quality health indicators among individuals receiving methadone in primary care centers in Ukraine.

作者信息

Machavariani Eteri, Bromberg Daniel J, Dumchev Kostyantyn, Esserman Denise, Earnshaw Valerie A, Pykalo Iryna, Filippovich Myroslava, Ivasiy Roman, Ahmad Bachar, Long Jiang, Haddad Marwan S, Madden Lynn M, Oliveros David, Dvoriak Sergii, Altice Frederick L

机构信息

Yale School of Medicine, Department of Medicine, Section of Infectious Diseases, New Haven, CT, United States; Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States.

Center for Interdisciplinary Research on AIDS, Yale University, New Haven, CT, United States; Yale School of Public Health, New Haven, CT, United States.

出版信息

Int J Drug Policy. 2025 Feb;136:104682. doi: 10.1016/j.drugpo.2024.104682. Epub 2024 Dec 19.

DOI:10.1016/j.drugpo.2024.104682
PMID:39705875
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11821433/
Abstract

INTRODUCTION

People who inject drugs experience poor health and social outcomes which improve with opioid agonist therapies like methadone, yet provider stigma may influence healthcare utilization. In Ukraine, integrating methadone into primary care centers (PCCs) provides an opportunity to examine provider stigma and its impact on patient outcomes.

METHODS

This sub-analysis included patients randomized to receive methadone in PCCs as part of an implementation trial in which the control group received methadone in specialty addiction clinics in Ukraine. Methadone integration in PCCs was supported through continuous tele-education for providers. Provider stigma towards people who inject drugs, methadone, and attitudes towards evidence-based practices were assessed at baseline, 12, and 24 months using standardized scales (range 1-10). Patient-level outcomes were measured bi-annually over 24 months using a quality health indicator (QHI) score, a percentage of guideline-concordant primary and specialty health services accessed. Linear mixed-effects models examined the changes in provider stigma and attitudes, and the association of these measures with patient outcomes.

RESULTS

The sample included 583 patients and the 112 providers in 24 clinics. Provider fear and stereotypes toward people who inject drugs improved significantly, by 0.6 (95 % CI 0.2-1.1) and 0.4 points (95 % CI 0.1-0.8), respectively, as did preference for methadone over abstinence-based treatment (0.7 points, 95 % CI 0.2-1.1). A 1-point improvement in provider prejudice correlated with a 7.0-point increase (95 % CI: 1.1-13.0) in patient primary care QHI scores at 12 months, while improved attitudes towards evidence-based practices were associated with an 8.3-point increase (95 % CI: 1.1-13.0). Preference for methadone maintenance over abstinence was associated with a 3.7-point increase (95 % CI: 0.6-6.7) in specialty care QHI scores at 12 months, and reduced stereotypes were associated with a 10.9-point increase (95 % CI: 1.2-20.7) at 24 months.

CONCLUSIONS

Integrating methadone into PCCs with the support of provider tele-education may reduce provider stigma, particularly fear and stereotypes, toward people who inject drugs and methadone maintenance. Reducing provider stigma has the potential to improve patient outcomes through increased access to preventive care and screenings.

摘要

引言

注射毒品者健康状况不佳且社会结局较差,而美沙酮等阿片类激动剂疗法可改善这些情况,但医疗服务提供者的污名化态度可能会影响医疗服务的利用。在乌克兰,将美沙酮纳入初级保健中心(PCC)为研究医疗服务提供者的污名化态度及其对患者结局的影响提供了契机。

方法

该子分析纳入了在PCC中随机接受美沙酮治疗的患者,这是一项实施试验的一部分,其中对照组在乌克兰的专科成瘾诊所接受美沙酮治疗。通过对医疗服务提供者进行持续的远程教育培训,支持在PCC中整合美沙酮。在基线、12个月和24个月时,使用标准化量表(范围为1 - 10)评估医疗服务提供者对注射毒品者、美沙酮的污名化态度以及对循证实践的态度。在24个月内,每半年使用质量健康指标(QHI)评分来衡量患者层面的结局,QHI评分是获得的符合指南的初级和专科医疗服务的百分比。线性混合效应模型研究了医疗服务提供者污名化态度和观念的变化,以及这些指标与患者结局之间的关联。

结果

样本包括24家诊所的583名患者和112名医疗服务提供者。医疗服务提供者对注射毒品者的恐惧和刻板印象分别显著改善了0.6分(95%置信区间0.2 - 1.1)和0.4分(95%置信区间0.1 - 0.8),对美沙酮相对于基于禁欲的治疗的偏好也改善了0.7分(95%置信区间0.2 - 1.1)。医疗服务提供者偏见每改善1分,与12个月时患者初级保健QHI评分提高7.0分(95%置信区间:1.1 - 13.0)相关,而对循证实践态度的改善与提高8.3分(95%置信区间:1.1 - 13.0)相关。在12个月时,对美沙酮维持治疗相对于禁欲的偏好与专科护理QHI评分提高3.7分(95%置信区间:0.6 - 6.7)相关,在24个月时,刻板印象的减少与提高10.9分(95%置信区间:1.2 - 20.7)相关。

结论

在医疗服务提供者远程教育培训的支持下,将美沙酮纳入PCC可能会减少医疗服务提供者对注射毒品者和美沙酮维持治疗的污名化态度,尤其是恐惧和刻板印象。减少医疗服务提供者的污名化态度有可能通过增加获得预防性护理和筛查的机会来改善患者结局。